BIOMx develops customized bacteriophage therapies to target and eliminate harmful bacteria associated with chronic diseases such as cystic fibrosis and diabetic foot osteomyelitis. By validating proprietary bacterial targets, the company creates tailored phage compositions that enhance treatment efficacy and patient outcomes.

The startup provides clinical research and development services focused on enhancing Amphotericin B to treat systemic and life-threatening fungal infections. Their approach enables the delivery of a broad spectrum of non-toxic antifungal drugs, improving patient safety and treatment efficacy.

Pattern Bioscience utilizes single-cell microbiology to provide rapid identification and antimicrobial susceptibility testing results within hours, bypassing traditional culture methods. The company addresses the issue of antibiotic misuse in hospitals, which leads to ineffective treatments and contributes to antibiotic resistance.

This clinical-stage biotechnology company utilizes machine learning to enhance the design and development of peptide therapeutics, focusing on precision engineering. Their lead candidate, PLG0206, is a broad-spectrum anti-infective currently in clinical trials for treating prosthetic joint infections, a condition with significant treatment challenges.

TenNor Therapeutics focuses on the research and development of novel pharmacological agents targeting digestive diseases, utilizing advanced drug discovery techniques and preclinical models. The company aims to improve treatment outcomes for patients suffering from conditions such as inflammatory bowel disease and gastrointestinal disorders.

Venatorx Pharmaceuticals develops novel anti-infectives targeting multi-drug-resistant bacterial and challenging viral infections through advanced drug discovery and development techniques. The company addresses the urgent need for effective treatments in the face of rising antibiotic resistance and limited therapeutic options.